A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0287 C (Insulin 287) for Subcutaneous Administration in Subjects With Type 2 Diabetes
Phase of Trial: Phase I
Latest Information Update: 03 Nov 2017
At a glance
- Drugs Insulin 287 (Primary) ; Insulin degludec
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 27 Oct 2017 Planned End Date changed from 1 Dec 2017 to 14 Dec 2017.
- 27 Oct 2017 Planned primary completion date changed from 1 Dec 2017 to 6 Dec 2017.
- 23 Nov 2016 Status changed from not yet recruiting to recruiting.